The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 6, 2010, Pages 803-809

  Artac, Mehmet ^a   Bozcuk, Hakan ^b   Pehlivan, Sacide ^c   Akcan, Songül ^b   Pehlivan, Mustafa ^c   Sever, Tugce ^c   Ozdogan, Mustafa ^b   Savas, Burhan ^b  

^a SELCUK UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

^c GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Colorectal cancer; Irinotecan; Overall survival; Single nucleotide polymorphisms; XPD; XRCC1

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA BINDING PROTEIN; DRUG DERIVATIVE; ERCC2 PROTEIN, HUMAN; IRINOTECAN; TUMOR MARKER; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CANCER STAGING; COLORECTAL TUMOR; COMPARATIVE STUDY; DNA REPAIR; DRUG EFFECT; FEMALE; FOLLOW UP; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 77951647467     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-009-0720-3     Document Type: Article

References (30)

1. Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6926
2. Balin-Gauthier D, Delord J-P, Pillaire M-J et al (2008) Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 98:120-128
3. Braun MS, Richman SD, Quirke P et al (2008) Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from UK MRC FOCUS Trial. J Clin Oncol 26:2690-2698
4. Carlini LE, Meropol NJ, Bever J et al (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11:1226-1236
5. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW (2003) A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 31:5526-5533
6. Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base no. 5, version 2.0. IARC Press, Lyon
7. Gurubhagavatula S, Liu G, Park S et al (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22:2594-2601
8. Hansen RD, Sorensen M, Tjønneland A et al (2007) XPA A23G, XPC Lys939Gln, XPD Lys751Gln and XPD Asp312Asn polymorphisms, interactions with smoking, alcohol and dietary factors, and risk of colorectal cancer. Mutat Res 619(1-2):68-80
9. Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH (2008) XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res 18(1):48-63
10. Hoskins JM, Marcuello E, Altes A et al (2008) Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 14(6):1788-1796
11. Iyer L, Ratain MJ (1998) Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 42(Suppl):S31-S43
12. Lenz HJ (2004) Pharmacogenomics and colorectal cancer. Ann Oncol 15(Suppl 4):iv173-iv177
13. Martinez-Balibrea E, Abad A, Aranda E et al (2008) Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. Eur J Cancer 44(9):1229-1237
14. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476-487
15. Monzo M, Moreno I, Navarro A et al (2007) Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first line oxaliplatin/fluoropyrimidine. Oncology 72(5-6):364-370
16. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61(24):8654-8658
17. Park SY, Lam W, Cheng YC (2002) X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res 62(2):459-465
18. Quinney SK, Sanghani SP, Davis WI et al (2005) Hydrolysis of capecitabine to 5′-deoxy-5-5-fluorocytidine by human carboxylesterases and inhibition by loperamide. J Pharmacol Exp Ther 313(3):1011-1016
19. Rea DW, Nortier JWR, Ten Bokkel Huinink WW et al (2005) A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 16(7):1123-1132
20. Ruzzo A, Graziano F, Loupakis F et al (2008) Pharmacogenetic proWling in patients with advanced colorectal cancer treated with first line FOLFIRI chemotherapy. Pharmacogenomics J 8:278-288
21. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914
22. Stelzner S, Hellmich G, Koch R, Ludwig K (2005) Factors predicting survival in stage for colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol 89:211-217
23. Stoehlmacher J, Ghaderi V, Iobal S et al (2001) A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21:3075-3079
24. Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91(2):344-354
25. Suh KW, Kim JH, Kim DY, Kim YB, Lee C, Choi S (2006) Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol 13:1379-1385
26. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash L (1993) Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature (Lond) 365:852-855
27. Taylor RM, Thistlethwaite A, Caldecott KW (2002) Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol Cell Biol 22:2556-2563
28. Ünal M, Güven M, Batar B, ÖzaydÂn A, Sarici A, Devranoglu K (2007) Polymorphisms of DNA repair genes XPD and XRCC1 and risk of cataract development. Exp Eye Res 85:328-334
29. Vallböhmer D, Iqbal S, Yang DY et al (2006) Molecular determinants of irinotecan efficacy. Int J Cancer 119:2435-2442
30. Wu J, Yin MB, Hapke G, Toth K, Rustum YM (2002) Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl- 10-hydroxy-camptothecin. Mol Pharmacol 61:742-748